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Displaceable binding of [3H]forskolin to human platelet membranes can be detected in the presence of mag- 
nesium. There is an increase in the number of [3H]forskolin binding sites when membranes are incubated 
with GppNHp or NaF in the presence of magnesium. ProstagIandin E,, which stimulates human platelet 
adenylate cyclase, does not affect the binding of [3H]forskolin in the absence of GppNHp. However, the 
dose-response curve for the GppNHp-dependent increase in [3H]forskolin binding sites is shifted to lower 
concentrations in the presence of prostaglandin E,. Prostaglandin E, potentiates the effect of GppNHp on 
[3H]forskolin binding most likely by facilitating the binding of the guanine nucleotide at the stimulatory 
quanine nucleotide regulatory protein of adenylate cyclase. 
Forskolia Adenylate cyclase Platelet 
1. INTRODUCTION 
The diterpene forskolin can activate most hor- 
monally responsive adenylate cyclases [ 1,2]. For- 
skolin has two apparently distinct actions in 
stimulating adenylate cyclase. Forskolin can ac- 
tivate adenylate cyciase directly with an EC50 of 
about 10 pM [3]. Forskolin can also potentiate 
hormonal stimulations of adenylate cyclase at con- 
centrations less than 0.1 ,uM [4,5]. Although for- 
skolin can activate adenylate cyclase in the absence 
of the stimulatory guanine nucleotide regulatory 
protein (N,) it has been shown that a maximal 
stimuIation of adenylate cyclase by forskolin does 
require the N, protein even in the absence of a hor- 
mone receptor agonist [6-81. It has also been 
shown that forskolin can stimulate adenylate 
cyclase at a high-affinity site which requires the N, 
protein [9]. 
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Receptor Binding Cyclic AMP 
We have recently described high-affinity binding 
sites for [3HJforskolin which have structure- 
activity requirements imilar to those required for 
the activation of adenylate cyclase by forskolin 
[IO]. These sites are sensitive to heat, N- 
ethylmaleimide, and trypsin or chymotrypsin [l l]. 
The maximal number of [3H]forskolin binding 
sites in rat brain membranes can be increased in the 
presence of NaF or GppNHp [l 11. We have pro- 
posed that these sites are associated with the for- 
mation of an activated complex of the N, protein 
and the catalytic protein of adenylate cyclase [l 11. 
Here we demonstrate that high-affinity forskolin 
binding sites can be detected in human platelet 
membranes and are increased in the presence of 
NaF or GppNHp. We also demonstrate that pro- 
staglandin El which stimulates adenylate cyclase in 
human platelets and potentiates forskolin stimula- 
tion of human platelet adenylate cyciase [4,12], 
can also potentiate the ability of GppNHp to in- 
crease [3H]forskolin binding sites. 
2. MATERIALS AND METHODS 
Platelet membranes were prepared fresh from 
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platelet rich plasma which had been drawn from 
healthy normal volunteers and was stored for 5-10 
days. Platelet-rich plasma was allowed to stand on 
ice for 10 min after addition of a l/5 vol. of 
10 mM Tris-HCl, pH 7.4, containing 0.1 M 
EDTA. The suspension was centrifuged at 3500 x 
g for 15 min and the supernatant discarded. The 
pellet was resuspended using a plastic pipette in 
8.6 mM TrislHCl, pH 7.4, containing 1.1 mM 
EDTA, 86 mM glucose, and 97 mM NaCl (buffer 
A). The suspension was centrifuged at 1000 x g for 
5 min to sediment erythrocytes. The supernatant 
was centrifuged at 3500 x g for 10 min. The pellet 
was resuspended in 12 ml buffer A and incubated 
for 10 min at 20°C with 3.8 ml of a 60% glycerol 
solution in buffer A. The platelets were centri- 
fuged at 5500 x g for 10 min, the supernatant 
discarded and the pellet resuspended in 20 ml of 
ice-cold 10 mM Tris-HCl, pH 7.4, containing 
25 mM sucrose and 2 mM EDTA for homogeniza- 
tion. The platelets were vortex-mixed vigorously 
for 2 min and homogenized with 5 strokes in a 
glass Dounce homogenizer. The membrane sus- 
pension was centrifuged at 25000 x g for 10 min 
at 4°C. The membrane pellet was washed twice 
with 10 mM Tris-HCl, pH 7.4, containing 1 mM 
EDTA and was resuspended in the same buffer. 
Membrane protein was determined by the method 
of Lowry et al. [13] using BSA as a standard. 
[3H]Forskolin binding was determined by in- 
cubating membranes (0.5 mg protein/assay) in a 
total volume of 0.4 ml of 50 mM Tris-HCl, pH 
7.4, with [3H]forskolin and additions as indicated 
for 1 h at 20°C. Nonspecific binding was deter- 
mined in the presence of 20 PM cold forskolin. The 
assay was terminated by the addition of 4 ml of 
ice-cold Tris-HCl, pH 7.4, and the bound for- 
skolin was separated by rapid filtration over What- 
man GFlC filters using a Brandel cell harvester 
(Gaithersburg, MD). The filters were washed with 
8 ml of buffer and placed in scintillation vials with 
5 ml scintillation fluid. Specific [3H]forskolin 
binding was calculated as the difference between 
total binding in the absence of unlabelled forskolin 
and nonspecific binding determined in the presence 
of 20pM unlabelled forskolin. Specific binding 
was normally about 80% of the total binding, 
however the nonspecific binding was found to in- 
crease if the membranes were stored frozen in Iiq- 
uid nitrogen. [‘H]Forskolin (27 Ci/mmol) was 
350 
synthesized as described in [lOI or was obtained 
from New England Nuclear (Boston, MA). 
3. RESULTS 
Saturable binding of [3H~forskolin to human 
platelet membranes can be observed in the 
presence of 5 mM MgClz (Nelson and Seamon, 
submitted). [3H]Forskolin binds to human platelet 
membranes in the presence of 5 mM MgClz with a 
&i of 20 nM. The Bmax for 13H~forskolin binding 
varies between 20 and 50 fmob’mg protein in the 
presence of 5 mM MgClz, NaF or GppNHp can in- 
crease the number of [3H]forskolin binding sites in 
human platelet membranes. In the presence of 
10 mM NaF or lOOaM GppNHp the number of 
binding sites is increased about 4-fold to 
100 fmol/mg protein (fig.1) at a concentration of 
10 nM [3H]forskolin. The combination of 10 mM 
NaF and 100/1M GppNHp does not produce a 
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Fig.1. Effect of GppNHp and NaF on [3H]forskolin 
binding to human platelet membranes. Membranes were 
incubated with 10 nM 13H)forskolin in the presence of 
5 mM MgC12, 1OOpM GppNHp, or 10 mM NaF for 1 h 
at 20°C. The number of [3H]forskolin binding sites in 
the presence of 5 mM MgClz alone was 29 f 1 fmol/mg 
protein. Data are representative of 3 separate 
experiments. Data are expressed as the mean + SE for 
triplicate determinations. 
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greater number of binding sites than that observed 
for either agent alone (fig.1). Magnesium is re- 
quired for the increase in [3H]forskolin binding 
sites observed in the presence of NaF or GppNHp. 
In the absence of magnesium there is no observed 
increase in forskolin binding sites by either 
GppNHp or NaF (fig.1). The increase in binding 
sites observed in the presence of NaF or GppNHp 
is associated with an increase in the B,,, for bind- 
ing with no detectable change in the Kd for the 
binding sites (not shown). In the presence of 10 
mM NaF and 5 mM MgC12, [3H]forskolin binds to 
human platelet membranes with a Kd of 18 nM and 
aB max of 400 fmol/mg protein (not shown). Near- 
ly identical binding parameters are obtained for 
[3H]forskolin binding to human platelet mem- 
branes in the presence of lOO/rM GppNHp. 
Prostaglandin Ei (10pM) does not affect the 
number of [3H]forskolin binding sites detected in 
the presence of 5 mM MgClz (fig.2). Prostaglandin 
Ei can, however, increase the efficacy of GppNHp 
to increase the number of [3H]forskolin binding 
sites. GppNHp increases [3H]forskolin binding 
with an ECso of about 0.6 PM, which is decreased 
to about 0.03 ,uM in the presence of 10 ,uM pro- 
staglandin Ei (fig.2). Prostaglandin El does not af- 
Fig.2. Effect of prostaglandin El on the GppNHp- 
induced increase in [3H]forskolin binding sites in human 
platelet membranes. Human platelet membranes were 
incubated at 20°C for 1 h with the indicated 
concentrations of GppNHp in the absence (0) or 
presence (0) of 1OpM prostaglandin El. Data are 
representative of 4 separate xperiments. Each point is 
the mean f SE of triplicate determinations. 
feet the maximal number of [3H]forskolin binding 
sites observed in the presence of high concentra- 
tions of GppNHp but only shifts the dose-response 
curve for the GppNHp-dependent increase in 
binding. 
4. DISCUSSION 
[3H]Forskolin binding sites in human platelet 
membranes can be detected which have similar 
characteristics as [3H]forskolin binding sites in rat 
brain membranes. These sites can be detected in 
the presence of 5 mM MgC12 alone. However, the 
maximal number of binding sites is observed in the 
presence of NaF or GppNHp. Under these condi- 
tions the sites have a Kd of about 20 nM with a 
B,,, of about 400 fmol/mg protein (not shown). 
The increase in binding sites detected in the 
presence of NaF or GppNHp requires the presence 
of magnesium. This has also been observed for the 
high-affinity [3H]forskolin binding sites in rat 
brain [ 111. NaF or GppNHp in the presence of 
magnesium activate the N, protein [ 14,151 and pro- 
mote the formation of the activated complex of the 
N, protein with the catalytic protein. We have 
previously suggested that the high-affinity for- 
skolin binding sites are associated with this ac- 
tivated complex and may represent a ternary com- 
plex of the catalytic protein of adenylate cyclase, 
the activated N, protein, and forskolin [ll]. 
Prostaglandin Er shifts the dose-response curve 
for the GppNHp-induced increase in [3H]forskolin 
binding. This shift is not associated with a change 
in Kd or a change in the maximal number of bind- 
ing sites that is observed with high concentrations 
of GppNHp. This suggests that the effect of pro- 
staglandin El is not directly on the [3H]forskolin 
binding sites but is associated with the binding of 
GppNHp at its site of action which is presumably 
the N, protein. Hormone binding to receptors can 
promote the exchange of guanine nucleotides at 
the N, subunit [16]. It therefore seems likely that 
prostaglandin Er promotes the binding of 
GppNHp at the N, protein resulting in the forma- 
tion of activated complexes of adenylate cyclase at 
concentrations of GppNHp which are lower than 
those required for activation of adenylate cyclase 
in the absence of hormone. 
Synergisms between forskolin and hormones 
have been observed for many hormonally respon- 
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sive adenylate cyclases. Forskolin and prostaglan- 
dins can synergistically activate adenylate cyclase 
in human platelet membranes [4,12]. The affinity 
of [3H]forskolin for its binding sites is very similar 
to the EC50 for forskolin’s potentiation of hor- 
mone effects. This suggests that the high-affinity 
binding sites for forskolin may be related to the 
sites which are responsible for forskolin’s potentia- 
tion of hormone stimulation of adenylate cyclase. 
The ability of prostaglandin Ei to modulate the 
number of high-affinity forskolin binding sites is 
consistent with this proposal. Hormonal potentia- 
tion of forskolin stimulation of adenylate cyclase 
could result from the hormone-induced formation 
of activated complexes of adenylate cyclase which 
would have a high affinity for forskolin. Converse- 
ly, forskolin could potentiate hormonal stimula- 
tion of adenylate cyclase by increasing the ap- 
parent binding affinity of the N, protein for the 
catalytic protein. 
In summary, high-affinity binding sites for 
13Hfforskolin are detected in human platelet mem- 
branes. The modulation of these sites by NaF, 
GppNHp, and prostaglandin Ei is consistent with 
these sites being associated with the formation of 
an activated complex of the catalytic protein of 
adenylate cyclase, the activated N, protein, and 
forskolin. The formation of this complex can be 
promoted by ligands which activate the N, protein 
and can be modulated by hormones which also 
promote activation of adenylate cyclase through 
the N, protein. 
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